Hugo Mathers
Reporter
Hugo joined Capital Brief after five years in government roles across London and Sydney. He also previously worked in venture capital with Europe's first proptech VC fund Pi Labs and edtech startup Primo Toys, and has written for Time Out, Urban List and The Mandarin.
Contact Hugo via email.
CSL chief executive Paul McKenzie has been called out for selling millions of dollars in shares in a torrid year for the ailing biotech giant.
Eligible users of Heidi’s AI-powered “medical scribe” will be able to buy into the company’s blockbuster USD65 million Series B, which closed earlier this month.
The exit comes just two years after Redactive was formed. The startup had raised $19 million in funding from Blackbird, Atlassian, Zapier and Felicis Ventures.
